Introduction
Acute myeloid leukaemia (AML) is a haematopoietic malignancy characterized by a block in cell maturation and an accumulation of undifferentiated blasts in the bone marrow and peripheral blood (Lowenberg et al, 2003 . AML is commonly treated with an induction chemotherapy, followed by a consolidation therapy and sometimes maintenance therapy (Buchner et al, 2005, Robak and Wierzbowska 2009) . As a postremission therapy, autologous or allogeneic bone marrow transplantation can be performed in selected patients (Shipley and Butera 2009) . For patients in first relapse older than 60 years and for patients resistant to standard chemotherapy, the immunoconjugate Gemtuzumab Ozogamicin (GO) is approved by the Food and Drug Administration (FDA) (Bross et al, 2001 , Sievers 2001 . GO is a CD33-specific antibody chemically coupled to the cytotoxic drug calicheamicin (Sievers et al, 1999 , Stasi 2008 . CD33, a 67-kDa transmembrane cell surface glycoprotein specific for the myeloid lineage, is not expressed on non-haematopoietic tissue but is expressed on a subset of normal haematopoietic stem cells (HSCs) and on AML leukaemia stem cells (AML-LSCs; Freeman et al, 1995 , Taussig et al, 2005 , Hauswirth et al, 2007 . In a phase II clinical trial, 30% of relapsed AML patients responded to GO, but severe side-effects were observed (Sievers 2001 , Larson et al, 2002 . In a recent European multicenter phase III study, GO was found to provide no benefit when administered as a post-remission therapeutic agent to older patients (Lowenberg et al, 2010) , and the drug is not approved in Europe. Furthermore, the agent displayed antigen-independent cytotoxicities towards CD33 negative cell lines (Bross et al, 2001 , Jedema et al, 2004 , Schwemmlein et al, 2006 . Despite of these problems GO clearly produces clinical benefits for a subgroup of AML patients, and CD33 is a validated target antigen. Still, new therapeutic modalities with fewer toxicities are urgently needed for the treatment of AML (Estey and Dohner 2006) . Another important AML-associated antigen is CD123, the alpha subunit of the interleukin-3 receptor (IL-3Rα), which is predominantly expressed on myeloid cells and on a (Moretti et al, 2001 ) and only in low density on HSCs (Huang et al, 1999 , Jin et al, 2009 ). However, CD123 has been detected in a variety of haematopoietic malignancies and on AML-LSCs (Jordan et al, 2000 , Munoz et al, 2001 , Testa et al, 2002 , Taussig et al, 2005 . Strikingly, CD123 shows a 4-fold increased expression on AML-LSCs over normal HSCs (Jin et al, 2009) . This finding together with the clinical observations, that elevated expression of CD123 in AML is associated with higher blast counts at diagnosis and a lower complete remission rate resulting in poorer prognosis (Testa et al, 2002 , Graf et al, 2004 , Testa et al, 2004 ) make CD123 a particularly interesting target for antibody-derived therapeutics (Jin et al, 2009 ).
AML-LSCs are known to possess several remarkable properties including self-renewal potential and increased resistance against chemotherapeutics and DNA damage (Lapidot et al, 1994 , Bonnet and Dick 1997 , Guan and Hogge 2000 , Guzman et al, 2001 , Hope et al, 2004 , Ishikawa et al, 2007 , Dick 2008 ). This unique cell population is thought to play a key role in the frequent occurrence of minimal residual disease (MRD) in relapsed AML patients after conventional chemotherapy (van Rhenen et al, 2005, Ravandi and Estrov 2006) . Hence, after the discovery of AML-LSCs a great amount of effort has been spent to investigate the surface antigen profile of this clinically relevant cell population to identify suitable markers for their targeted elimination (Jordan et al, 2000 , Taussig et al, 2005 , Jin et al, 2006 , Hosen et al, 2007 , Jin et al, 2009 . The fact that both antigens, CD33 and CD123, are expressed on AMLLSCs offers novel prospects for the treatment of AML. So far an immunotoxin (Du et al, 2007) , a fusion of IL-3 with a truncated version of diphtheria toxin (Feuring-Buske et al, 2002 , Frankel et al, 2008 , a neutralizing full-length antibody (7G3; Jin et al, 2009) , and a bispecific single-chain Fv (bsscFv; Stein et al, 2010) directed against CD123 have been described, and the monoclonal antibody 7G3 has been tested in a phase I clinical study (Roberts et al, 2008;  http://clinicaltrials.gov/ct2/show/NCT00401739?term=CSL360&rank=1). Well-studied antibody-derived agents directed against CD33 include apart from GO an immunotoxin (Schwemmlein et al, 2006) , a fusion protein between a single chain Fv antibody fragment (scFv) and the sTRAIL death receptor ligand (ten Cate et al, 2009) , and siRNAloaded liposomes coated with CD33-directed scFvs (Rothdiener et al, 2010) .
BsscFvs have advantageous properties over full-length bispecific antibodies and chemically coupled bispecific Fragment antibody binding (Fab) fragments, and have recently produced convincing therapeutic effects in clinical trials (Bargou et al, 2008) . To overcome some of the remaining weaknesses of this format, such as an unfavorable plasma retention, the format has been further improved by expanding it to tandem diabodies (Kipriyanov et al, 1999) and single-chain triplebodies (sctbs; Kellner et al, 2008) . The incorporation of a second scFvbinding site for tumour-antigens in these extended formats has led to increased avidity for the tumour cell, increased anti-tumour activity in antibody dependent cellular cytotoxicity (ADCC) reactions, and improved plasma retention in vivo (Kellner et al, 2008) . An example for a sctb with improved ADCC activity for AML cells is the sctb [33 x ds16 x 33] (Singer et al, 2010) with two scFv antigen binding sites for CD33 on AML cells and one for CD16, the low affinity Fcγ RIII receptor for IgG on NK cells and macrophages (Ravetch and Perussia 1989, Daeron 1997) . In a direct comparison, this sctb showed increased anti-leukaemic activity for AML cells over the corresponding bsscFv [33 x ds16] with only one binding site each for CD33 and CD16. Before these trivalent single-polypeptide formats, other trispecific antibody derivatives had been explored. One example was a trispecific Fab construct, consisting of three chemically coupled Fab-fragments (Somasundaram et al, 1999) . A second trispecific construct was called a "tri-body", a two-chain polypeptide based on a Fab fragment as scaffold (Schoonjans et al, 2001) . Two scFvs were fused to the C-termini of the L-and Fdchains of this Fab, respectively. Finally, a trispecific molecule based on a VH domain has been reported, which carried two scFvs fused to a VH-domain (Song et al, 2003) . The key molecule presented here, the sctb [123 x ds16 x 33], differs significantly in its design from all of these examples. It is a single-chain polypeptide with only one binding site for an effector cell and two for two different tumour antigens, CD123 and CD33. The goal of this design was to achieve improved anti-leukaemic activity by "dual targeting" of the tumour cell, i.e. by simultaneous binding to two different antigens on the same tumour cell. We expected this molecule to bind with greater avidity to CD123 and CD33 on double-positive AML cells than the corresponding control sctbs [123 x ds16 x 123] and [33 x ds16 x 33], because it would take advantage of two populations of target antigens rather than only one. Based on theoretical arguments, the avidity of such proteins was expected to be proportional to the combined target antigen density on the tumour cell (Mattes 1997, Pluckthun and Pack 1997) .
The prediction of added benefits by dual-over mono-specific targeting of tumour cells is intuitively appealing, and has been pursued for a number of years (Robinson et al, 2008 ), but
has not yet been conclusively proven for scFv-derived agents recruiting effector cells. A definitive proof of this prediction is experimentally demanding and is still under investigation.
However, indirect evidence in favour of the proposition has been obtained for scFvimmunotoxins, and therefore, the concept may also extend to agents recruiting effector cells (Vallera et al, 2005) . The molecules presented here provide an opportunity to directly evaluate the benefits of dual over mono-specific targeting for AML cells. Finally, they provide new means to test the prediction that dual targeting a combination of two antigens, which are more highly expressed on AML-LSCs than on HSCs, may permit the preferential elimination of AML-LSCs. It would be important to test this prediction, because if confirmed it would provide a possibility for a deliberate attack on the LSCs with the intent to eliminate MRD cells and prevent relapse, while preserving some HSCs for haematopoietic reconstitution after the end of treatment, without the need for autologous stem cell transplantation.
The molecules presented here provide first steps towards these important goals of rational leukaemia therapy. 
Materials and Methods

Cell lines and hybridomas
The human AML cell lines MOLM-13, THP-1 (t(9;11)(p22;q23), expressing MLL-MLLT3) and U937 were from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). Chinese hamster ovary (CHO) cells, stably transfected with a human CD16 cDNA expression vector, were provided by Dr. J. van de Winkel (University of Utrecht, the Netherlands). The hybridoma 3G8; FcγRIII, CD16; IgG1, (Fleit et al, 1982) and the human 293T and 293 cells were from the American Type Cell Culture Collection (ATCC, Manassas, VA, USA). The 4G7 hybridoma (CD19; IgG1) was from Dr R. Levy (Stanford University, Palo Alto, CA; (Meeker et al, 1984) . CHO, THP-1, U937 and the 3G8 hybridoma cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 Glutamax-I medium (Invitrogen, Karlsruhe, Germany) containing 10% fetal calf serum (FCS; Invitrogen), 100 units/ml penicillin (Invitrogen), and 100 µg/ml streptomycin (Invitrogen). MOLM-13 cells were cultured in RPMI 1640 Glutamax-I medium containing 20% FCS, 100 units/ml penicillin and 100 µg/ml streptomycin (Invitrogen). Human 293, 293T and 293 cells stably transfected with CD123 were maintained in DMEM (Invitrogen) Glutamax-I medium containing 10% FCS, 100 units/ml penicillin and 100 µg/ml streptomycin (Invitrogen). The medium for the CD123 expressing cells further contained 400 µg/ml Geneticin (Invitrogen).
Construction of sctbs [123 x ds16 x 33] and [123 x ds16 x 123]
Escherichia coli strain XL-1 blue (Stratagene, Amsterdam, The Netherlands) was used as host for the amplification of plasmids and cloning. For the construction of the sctb [123 x ds16 x 33] expression vector the sequence coding for the CD123-specific scFv was excised from the vector pAK400-CD123scFv and cloned as a SfiI-cassette into the existing vector pSecTag2HygroC-STREP-His-CD33xdsCD16xCD33 (Singer et al, 2010) (Bruenke et al, 2004) . To generate the vector pSecTag2HygroC-STREP-His-CD123xdsCD16xCD123, the sequence coding for the CD123-specific scFv was amplified by PCR from the vector pAK400-CD123scFv and ligated into pSecTag2HygroC-STREP-His-CD123xdsCD16xCD33, using XhoI/EcoRV restriction sites, and replacing the coding sequence for the C-terminal CD33-specific scFv. For construction of the expression vector pSecTag2HygroC-hCD123ex-DsRed, cDNA coding for the extracellular domain of CD123 was amplified by PCR using the existing vector pSecTag2HygroC-hCD123ex-Fc and ligated into the vector pSecTag2HygroC-CD33ex-DsRed (Singer et al, 2010) , replacing the extracellular domain of et al., 1989) . The transfection medium was replaced by fresh culture medium after 10 h and for 5 d supernatants were collected every day and combined. Supernatants were analyzed for the presence of antibody fragments by flow cytometry. The recombinant Histagged proteins were enriched by affinity chromatography using nickel-nitrilotriacetic acid agarose (NTA) beads (Qiagen, Hilden, Germany) and dialyzed against phosphate-buffered saline (PBS). Fusion proteins with green or red fluorescence protein were transiently expressed in 293T cells and purified as described above.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blot analysis
Eluted proteins were analyzed by reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) using standard procedures (Laemmli, 1970) . Gels were stained with Coomassie brilliant blue R250 (Sigma-Aldrich, Taufkirchen, Germany). In Western blot experiments, recombinant proteins were detected with an unconjugated penta-His antibody (Qiagen) and a secondary horseradish peroxidase-coupled goat anti-mouse IgG antibody (Dianova, Hamburg, Germany). Western Blots were developed using enhanced chemiluminescence reagents (Amersham Pharmacia Biotech, Freiburg, Germany).
Flow cytometry analysis
Immunofluorescence analysis was performed on a FACSCalibur instrument using CellQuest software (Becton Dickinson, Heidelberg, Germany) as described (Schwemmlein et al, 2006) . Briefly, 1 x 10 4 events were collected for each sample, and whole cells were analyzed using appropriate scatter gates to exclude cellular debris and aggregates. The recombinant sctb proteins were detected using a penta-His antibody and a PE-conjugated goat anti-mouse-IgG 
Determination of equilibrium binding constants (K D )
K D values were determined by calibrated flow cytometry as described (Benedict et al, 1997) .
The highest mean fluorescence value was set to 100%, and all data points were normalized to this value. The experiments were repeated 6 times. The K D values were calculated using a nonlinear regression curve fit.
Measurement of in vitro serum stability
To determine the in vitro serum stability of sctbs [123 x ds16 x 33] and [123 x ds16 x 123], aliquots of the recombinant proteins were incubated at a sub-saturating concentration of 2.5 µg/ml at 37°C (day 5) in human serum or stored at -20°C and thawed at defined time points (day 0-4). The residual binding activity was measured by flow cytometry on day 0 (as described above). The experiment was repeated at least 4 times and results were fitted to a monoexponential decay.
Isolation of mononuclear cells (MNCs) and AML cells from human donors
Citrate buffered or heparinized peripheral blood from both healthy volunteers and AML patients or bone marrow from AML patients were obtained after receiving informed consent and with the approval of the Ethics Committee of the University of Erlangen-Nuremberg.
MNCs were enriched by Lymphoflot (Biotest, Dreieich, Germany) Ficoll density centrifugation in Leukosep tubes (Greiner, Frickenhausen, Germany) according to manufacturer's instructions, and suspended in RPMI 1640 Glutamax-I medium containing 10% FCS, 100 units/mL penicillin and 100 mg/mL streptomycin. Viability was verified by Trypan blue exclusion and exceeded 95%. 
ADCC reactions
ADCC assays, using MNCs from healthy donors as effector cells, were performed in triplicates using a 3-hour 51 Cr release assay as described (Elsasser et al, 1996) . For blocking experiments, the parental antibody 3G8, the IgG1 isotype control, the CD123-and CD33-specific scFvs and the control scFv were added at a 125-fold and 500-fold molar excess, respectively. Dose-response curves were recorded using several equimolar 5-fold serial dilutions of the respective antibody fragments at a constant effector-to-target-cell (E:T) ratio of 40:1 MNCs to target cells. Background lysis induced by MNCs alone was subtracted from each data point, and EC 50 values (concentration of an antibody fragment producing 50% of maximum specific lysis) and maximal lysis were calculated by using a sigmoidal doseresponse curve fit. The experiments were repeated 6 times and mean values are reported, unless otherwise stated.
ADCC reactions with enriched NK cells
NK cells were enriched from the MNC fraction using a NK cell isolation Kit (Miltenyi, Bergisch Gladbach Germany) and immunomagnetic bead (MACS) technology following manufacturer's protocols. Purities ranged from 83 to 98% as judged by 2-colour flow cytometry using FITC-coupled CD16-specific antibodies (Beckman Coulter) and PC7-conjugated CD56-specific antibodies (BD Biosciences, Heidelberg, Germany) according to the manufacturer's instructions. Flow cytometric analysis was performed on a FC 500 flow cytometer (Brea, CA). Isolated NK cells were cultured overnight at a density of 2 x 10 6 cells/ml in RPMI 1640 Glutamax-I medium (Invitrogen) containing 10% FCS (Invitrogen), 100 units/ml penicillin (Invitrogen), and 100 µg/ml streptomycin (Invitrogen). Cytotoxicity reactions were performed in an E:T cell ratio of 10:1 in a standard 4 h 51 Cr as described above. After 4 hours of incubation, 25 µl of supernatant was mixed with scintillation solution 
Graphical and statistical analysis
Graphical and statistical analyses were performed using Graph Pad Prism Software (Graph Pad Software Inc, San Diego, CA) and Microsoft EXCEL. Group data were reported as means ± standard error of the mean (SEM). Differences between groups were analyzed using paired Student t test. P values < 0.05 were considered significant. (Singer et al, 2010 (Fig 1A) . (Fig 2A) . Equilibrium binding constants of the dual targeting sctb were 18.8 ± 0.9, 17.8 ± 2.2, and 21.7 ± 1.8 nM for the reactions with CD123, CD33 and CD16 on single-positive cells, respectively (Table II) (Fig 3A) . Therefore, all three scFvs within the sctb [123 x ds16 x 33] specifically reacted with their respective antigens.
To test whether sctb [123 x ds16 x 33] was able to bind to more than one antigen simultaneously, CD33 single-positive U937 cells were incubated with the sctb and stained in parallel with the recombinant proteins CD123ex-RFP and CD16ex-GFP (Fig 3B) . These proteins contained the extracellular domains of the surface proteins CD123 and CD16, genetically fused to the red and green fluorescence proteins, respectively. As a result, the target cells showed green and red fluorescence, indicating that the sctb mediated binding of both CD123ex-RFP and CD16ex-GFP to the same target cell.
To determine the in vitro serum stability of sctbs [123 x ds16 x 33] and [123 x ds16 x123], the recombinant proteins were incubated in human serum at 37°C for different lengths of time.
Residual binding activity was measured by flow cytometry and ranged between 81% and 94% on day 5 for each scFv on respective single-positive cell lines. Therefore, stability for both molecules for at least 5 days was confirmed (Table I) . (Fig 5) . Co-incubation with a simultaneous 500-fold molar excess of both CD33-and CD123-specific scFvs completely blocked lysis of MOLM-13 cells, whereas competition with either scFv alone reduced target cell lysis only to about half-maximum value. Therefore, both scFvs specific for CD33 and CD123 contained within the triplebody must have contributed to the ADCC reaction. Also, co-incubation with a 125-fold molar excess of the parental CD16-specific monoclonal antibody 3G8 but not with an IgG1 isotype control antibody (4G7), significantly reduced lysis of MOLM-13 cells, highlighting the specificity in triggering CD16 + effector cells.
ADCC of established AML
ADCC of the established AML-derived cell line MOLM-13 mediated by sctbs [123 x ds16 x 33] and [123 x ds16 x 123] and enriched NK cells
To investigate whether the sctbs were able to activate CD16 + effector cells not only within the MNC fraction but also to directly activate purified CD16 + NK cells, NK cells sorted with immunomagnetic beads were used in ADCC reactions (Fig 4C) . Purified NK cells and MOLM-13 cells were used at an effector-to-target-cell ratio of 10:1 with triplebody concentrations of 1 nM in 3 independent experiments. Both sctbs mediated similar significant lysis (~60%) of AML cells compared to a control sctb. No specific lysis was observed when samples were incubated in the absence of NK cells. These results show first, that the sctbs were able to directly activate purified CD16 + NK cells in ADCC reactions; second, that the proteins alone without effector cells had no effect on the target cells; and third, that the protein preparations were therefore free of cytotoxic contaminants. et al, 2010) was also carried along. All three sctbs showed potent lysis of primary AML cells in a concentration-dependent manner (Fig 6) . Four representative ADCC reactions of samples from patients 1 and 2 (peripheral blood; Fig 6A+B) and patients 6 and 7 (bone marrow; Fig   6C+D) are depicted. At a concentration of 5 nM, all three recombinant proteins produced potent specific lysis (Fig 6E) . In 4/8 samples, the dual targeting sctb [123 x ds16 x 33] reached the highest extent of lysis. This finding was confirmed when ADCC data from all six peripheral blood samples were combined (Fig 6F) , in which the recently gained knowledge, that addition of a second scFv binding site for a tumour antigen leads to increased anti-tumour activity (Kellner et al, 2008) , has been incorporated. (Kellner et al, 2008 , Singer et al, 2010 . This may be due to differences in antigen density for CD33 and CD123 on double-positive cells, to differences in accessibility of both antigens or their spatial segregation into different subdomains. However, the result clearly indicates that both scFvs respectively. This highlights a 3-fold gain in affinity for CD123 compared to the dual targeting sctb [123 x ds16 x 33], which must be due to an avidity effect caused by the addition of a second CD123-specific scFv in the mono targeting protein. This result is a further clear indication that both antigens actively participate in binding to the target cell, confirming earlier findings for this molecular format (Kellner et al, 2008 , Singer et al, 2010 . Another important parameter for antibody-derivatives is stability. When administered into the blood stream as therapeutic agents, such molecules need to be stable against degradation and unfolding (Carter 2006) . Both proteins have been tested and were stable in human serum at Remarkably, simultaneous co-incubation with both scFvs completely abolished cell lysis, indicating that both binding moieties played an active role not only in binding to the tumour cell but also in mediating ADCC. The same is true for CD16. Co-incubation with the CD16 monoclonal antibody 3G8 reduced the measured cell lysis to such an extent that it was no classifications. These samples showed a high variability in the response to the sctbs ( Figure   6A -E). This is most likely due to the highly heterogenous nature of the AML, with many subtypes characterized by different genomic alterations, different disease phenotypes, disease progression and responses to treatment . Therefore, a broad variability both in the fraction of total cells expressing CD33 and CD123 and cells susceptible to ADCC lysis mediated by our recombinant proteins was to be expected and had also been previously observed for the susceptibility to the CD33-ETA' immunotoxin (Schwemmlein et al, 2006) . It would be interesting in the future to study, whether the CD34 + CD38 -compartment of primary AML-cells, obtained by preparative sorting, which contains the AML-LSCs, shows a stronger extent of ADCC-lysis than other compartments devoid of AML-LSCs. Until now, these experiments could not be performed due to limited availability of primary patient cells.
Recent studies gave rise to the concept that CD16-positive monocytes/macrophages may play a vital role as effector cells in vivo mediating anti-tumour effects of therapeutic antibodies (Uchida et al, 2004 , Tedder et al, 2006 . In particular, their role in the elimination of AML F o r P e e r R e v i e w 21 cells by phagocytosis has been extensively studied ). In our experiments, CD16-positive NK cells represented the main effector cell population in purified MNCs, a leukocyte fraction devoid of monocytes/macrophages. It will be an important question for the future to determine, whether our triplebodies are able to activate not only NK cells by monovalent binding to CD16 but also CD16-positive macrophages.
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